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Abstract: In this study, our aim was to describe QoL prevalence and 
heterogeneity in QoL reporting in colorectal cancer phase III trials.  
We included all phase III trials evaluating anticancer drugs in 
colorectal cancer patients published between 2012 and 2018 by 11 major 
journals.  
Out of the 67 publications identified, in 41 (61.2%) QoL was not listed 
among endpoints. Out of 26 primary publications of trials including QoL 
among endpoints, QoL results were not reported in 10 (38.5%). Overall, no 
QoL data were available in 51/67 (76.1%) primary publications. In 
particular, in the metastatic setting, QoL data were not available in 
12/18 (66.7%) trials with primary endpoint overall survival, and in 20/29 
(69.0%) trials with other primary endpoints.  
QoL was absent in a high proportion of recently published phase III 
trials in colorectal cancer, even in trials of second or further lines, 
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Dear Editor, 
On behalf of my colleagues, I am submitting the manuscript: “Quality of life (QoL) 
assessment and reporting in colorectal cancer: a systematic review of phase III 
trials published between 2012 and 2018.” for consideration for publication in Critical 
Reviews in Oncology/Hematology.  
This work follows our previous publication in Annals of Oncology (Marandino L. et 
al. Deficiencies in health-related quality-of-life assessment and reporting: a systematic 
review of oncology randomized phase III trials published between 2012 and 2016. Ann 
Oncol. 2018 Dec 1;29(12):2288-2295.). Compared to the Annals of Oncology work, the 
manuscript has updated including also the trials published in 2017 and 2018 and we 
focused on colorectal cancer patients. 
The analysis is based on 67 publications. Overall, due to absent endpoint or 
unpublished results, QoL data were absent in 51 (76.1%) primary publications (95.0% in 
adjuvant/neoadjuvant setting, 69.2% in first line, and 66.7% in second and further lines). 
Interestingly, this data doesn’t change over time: QoL was not reported in 74.4% 
publications between 2012 and 2015 vs. 79.2% between 2016 and 2018. 
Furthermore, in metastatic patients where attention to QoL could be essential, QoL 
data were not available in 66.7% trials with primary endpoint overall survival and in 69.0% 
trials with other primary endpoints. 
We hope that this analysis can be interesting and stimulating, challenging the 
research community to adopt more QOL outcomes in trials, and the scientific community to 
give the adequate focus on QoL when reading results of cancer studies. We hope that this 
topic can be of interest for the readers of Critical Reviews in Oncology/Hematology.  
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Reviewers' comments: 
 
Reviewer #1: In this paper, the authors provide a comprehensive review of quality of life (QoL) data 
from recent phase III clinical trials conducted in colorectal cancer patients. First demonstration: few 
studies included QoL results. Furthermore, the authors show great heterogeneity in QoL methods 
of analysis and presentation of results. The rigourous and scientific approach gives important 
information and nicely describe the current status of knolwdge on the topic. The topic of QoL 
assesment is quite hot, especially in advanced setting, when benefits and side effects should be 
well balanced in clinical decision making. 
Some points could be improved: 
1) Methods: how the authors selected the 11 journals for their review? It is not clear and should be 
specified in the text. 
We thank the reviewer for the comment. We have included in this work all the journals considered 
in our previously published systematic review (Marandino et al, Annals of oncology, 2018 Dec, 
PMID: 30304498).  Despite we have focused the analysis on colorectal cancer, we limited the 
update to the same 11 journals included in the previous analysis because they represent, in our 
opinion, the highest impact factor journals where large oncology randomized clinical trials are 
usually published. 
We acknowledge that this limitation could have excluded some randomized trials published in other 
journals in the period included in the analysis. We have modified the paragraph in the Methods 
section, to better clarify this aspect.  
 
2) Results: no data are reported on correlation between gain or loss in QoL and trials results 
(positive vs negative): did the authors analyzed this aspect? Do they think that this could influence 
QoL reporting? 
We thank the reviewer for the comment. We think that is a very interesting point but it is inherently 
difficult to verify. Indeed, we were able to verify the direction of QoL results only when these are 
published in a primary publication or in a secondary one.  
A bias favoring the publication of positive results is reasonable, and we could have in literature a 
higher percentage QoL data for positive studies.  However, this remains a limited observation, 
because we would need to verify the direction of all the QoL results, even when not published. 
However, we acknowledge that this comment is very useful, and we added to Table 2, Table 3 and 
Table 4 (reporting the details of each study included in the analysis) the details of QoL results 
(positive or negative) when available.  
Indeed, among 32 trials with positive results, all the 12 trials including QoL among study endpoints 
(37.5%) reported QoL results in the primary publication: 5 trials reported a positive QoL result, 
while 7 trials reported negative QoL results.  
On the contrary, among 35 trials with negative results, despite 14 of these trials included QoL 
among endpoints, only 4 (11.4%) include QoL results in the primary publication: all these trials 
reported a negative QoL result. In 5 cases we have only a secondary publication: also in this case, 
all trials reported negative QoL results.  In the remaining 5 trials including QoL as an endpoint, 
results have not been published. 
These data are summarized in the graph below (that we report for Reviewer only): 
 






In summary, these data show that the chance of publication of QoL results is higher in trials that 
are positive for the primary endpoint compared to trials that are negative for the primary endpoint. 
However, within positive trials, QoL results are not necessarily in the same direction (being 
negative in more than half of the 12 positive trials with available QoL results) and their inclusion in 
the publication is useful for a more complete and balanced evaluation of treatment value.  
 
4) Few grammatical and typing errors are present. Check carefully. 
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Background: In this study, our aim was to describe QoL prevalence and heterogeneity in 
QoL reporting in colorectal cancer phase III trials. 
Methods: We included all phase III trials evaluating anticancer drugs in colorectal cancer 
patients published between 2012 and 2018 by 11 major journals.  
Results: Out of the 67 publications identified, in 41 (61.2%) QoL was not listed among 
endpoints. Out of 26 primary publications of trials including QoL among endpoints, QoL 
results were not reported in 10 (38.5%). Overall, no QoL data were available in 51/67 (76.1%) 
primary publications. In particular, in the metastatic setting, QoL data were not available in 
12/18 (66.7%) trials with primary endpoint overall survival, and in 20/29 (69.0%) trials with 
other primary endpoints.  
Conclusions: QoL was absent in a high proportion of recently published phase III trials in 
colorectal cancer, even in trials of second or further lines, where attention to QoL should be 
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Colorectal cancer (CRC) represents the third most common cancer affecting both men 
and women worldwide1. Although metastatic CRC (mCRC) remains a highly lethal disease, 
recent advances in the outcome of these patients have been achieved. This prognostic 
improvement could be attributed to several factors, including the availability of new drugs 
and/or new combinations, with a median overall survival (mOS) considerably increased from 
12 months in the 5-fluorouracil (5-FU)-based chemotherapy era to approximately 30 months 
observed in recent clinical trials2,3. 
Notwithstanding the increased anti-tumoral activity and efficacy of systemic treatments, 
the impact of drug toxicity, that could negatively affect patients’ quality of life (QoL), should 
not be forgotten, particularly in those clinical settings characterized by a limited life 
expectancy and a more delicate balance between benefits and harms of treatment. In the 
latter settings, uncertainty could remain concerning the net clinical benefit, especially for 
patients with chemo-refractory mCRC treated in and beyond third-line setting. In these 
patients, several drugs recently approved for use in clinical practice, like regorafenib and 
TAS-102, produce a modest survival benefit, with not negligible toxicity issues4,5. Therefore, 
particularly in this scenario, an integrated analysis of “cost-benefit” ratio for the patient should 
become mandatory6, as well as the evaluation of patients’ experience with patient reported 
outcomes (PROs). 
PROs, which are outcomes assessed directly by the patient7, may produce a different 
patients’ perspective on the disease and treatment received, complementing the conventional 
reporting of anti-tumor efficacy data and the physician-based description of adverse events 8. 
Health-related quality of life (HRQoL) is a specific type of PRO which evaluates the patient’s 
perspective “of the impact of his disease and its treatment(s) on his daily life, physical, 
psychological and social functioning and well-being”7. In dedicated documents, European 
Medicines Agency (EMA) and Food and Drug Administration (FDA) emphasized the 
importance of the impact of treatments on health-related quality of life in everyday life7,9. 
These aspects are crucial for the evaluation of the clinical benefits of new drugs. Indeed, 
PROs provide data on patient's QoL, symptoms, treatment adherence or satisfaction with 
care by including any information directly reported by the patient himself/herself on his/her 
perception of the disease and its treatment. PROs try to capture a personal perspective, that 
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may vary from person to person, using well-established methods. PROs should be more 
widely used to complement the range of traditional indicators of efficacy in oncology and 
provide information regarding both positive and negative patient experiences. Moreover, in 
2015, both American Society of Clinical Oncology (ASCO) and the European Society of 
Medical Oncology (ESMO) proposed frameworks to quantify the benefit of oncology 
medications, and QoL is included in both instruments10,11. 
In a previous systematic review, not specifically focused on CRC, we showed that QoL 
was not included among endpoints in a high proportion (210 of the 446 publications analyzed, 
47%) of oncology phase III randomized trials published by major journals between 2012 and 
2016. In addition, even when QoL was included among study endpoints, we found that QoL 
results were significantly underreported and often affected by a significant delay in 
publication12.  
Aim of this systematic review is to describe QoL prevalence as an endpoint in 
randomized phase III trials testing anticancer drugs in colorectal cancer patients, published 
between 2012 and 2018. In addition, we described the underreporting of QoL results and 






Articles published by 11 major scientific journals, already selected for our original 
analysis in all solid tumors as the journals where oncology randomized controlled trials are 
usually published 12, were retrieved for this update spcecifically focused on colorectal cancer 
trials. Namely, our search included 3 general medical journals (New England Journal of 
Medicine, Lancet, JAMA) and 8 oncology journals (Lancet Oncology, Journal of Clinical 
Oncology, JAMA Oncology, Journal of the National Cancer Institute, Annals of Oncology, 
European Journal of Cancer, British Journal of Cancer, Cancer). With the aim to identify 
primary publications of randomized phase III trials testing anticancer drugs in patients with 
solid tumors, all issues of the mentioned journals published between January 2012 and 
December 2018 were hand-searched. The original analysis12, limited to papers published 
between 2012 and 2016, has been updated for the present analysis, with the addition of 
articles on CRC published in 2017 and 2018.  
Trials testing non-pharmacologic interventions were excluded from the analysis. Both 
trials conducted in early stages of disease (e.g., adjuvant chemotherapy, neo-adjuvant 
chemo-radiotherapy) and trials conducted in advanced / metastatic setting were included, 
while trials testing prevention strategies were excluded.  
To collect data from each selected paper, the same dedicated case report form used 
for the previous analysis12 was adopted, and the electronic database, with one record for 
each paper, was updated. For each trial, information about publication (journal, year, first 
author, date of definitive issue and ahead-of-print publication, availability of online 
supplemental material and/or study protocol) was collected. Impact factor (IF), corresponding 
to the year of each publication, was retrieved from the Journal of Citation Reports, and 
publications were divided into 3 categories according to IF: low (<15), intermediate (15-30), 
high (>30). Information recorded about the clinical trial included: sponsorship (for-profit vs. 
non-profit), study design (open-label vs. blinded; superiority vs. non-inferiority), details of 
treatment of both experimental and control arms, disease setting. Articles were divided in 3 
categories: (i) adjuvant or neoadjuvant treatment in early stages; (ii) first-line treatment for 
metastatic disease; (iii) second and/or further lines of treatment for metastatic disease. 
Similarly to our previous analysis, trials were classified as for-profit when sponsored by the 
drug company and as non-profit when sponsored by an academic institution or a cooperative 
group, even if receiving drug supply and/or economic support from one or more drug 
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companies (when not explicated in the publication, details about the study sponsorship were 
retrieved from ClinicalTrials.gov study record, if available). Experimental treatments were 
classified into 2 main groups (that were not mutually exclusive): chemotherapy +/- other 
drugs; targeted agents +/- other drugs. According to study results in terms of primary 
endpoint, clinical trials were classified into positive or negative.  
Information about study endpoints (both primary and secondary, tertiary or exploratory) 
was derived from the Methods section of the publication and/or from the study protocol (when 
available as online supplementary material). When QoL was not listed among endpoints in 
the paper and study protocol was not available, QoL was considered as “apparently absent”, 
except when QoL results were actually presented in the Results section or in a secondary 
publication: in the latter case, QoL was included de facto among endpoints. For all records, 
secondary QoL publications were searched in PubMed, by using the name of the drug(s) 
and/or the name of authors of the primary publication and/or the study acronym / code, when 
available. Time to secondary QoL publication was calculated according to Kaplan-Meier 
method, from the date of primary definitive publication to the date of secondary QoL definitive 
publication, if existing, or to the date of last PubMed check (February 15th, 2019).  
Details of QoL methodology (type of QoL tools adopted, type of statistical analysis and 
presentation of results) were collected. As for type of statistical analysis, several non-mutually 
exclusive categories were identified: mean scores at different time points, mean changes from 
baseline, proportion of responding patients, time to deterioration. Among details of QoL 
methodology, we verified whether statistical approaches for dealing with missing data were 
explicitly stated in the paper and whether data about compliance to QoL questionnaires were 
reported in the publication.  







3.1 Study characteristics 
Overall, 67 eligible publications were identified. The main characteristics of the eligible 
publications are reported in Table 1 (the complete list is reported in the table 2 - 4).  
The three most represented journals were Lancet Oncology (20 papers, 29.9%), 
Annals of Oncology (18 papers, 26.9%) and Journal of Clinical Oncology (14 papers, 20.9%). 
Median IF of the eligible publications was 18.038 (interquartile range 11.612—26.303, 
range 4.819—59.558).  
The majority of trials (47, 70.1%) were conducted in patients with advanced/metastatic 
disease, but studies are well distributed among the 3 setting categories that we defined for 
classification: adjuvant/neoadjuvant setting (20, 29.9%), first-line or maintenance setting (26, 
38.8%) and second and further lines setting (21, 31.3%). Experimental treatment was 
chemotherapy ± other drugs in 52 trials (77,6%) and targeted therapy ± other drugs in 40 
trials (59,7%). More than one-third of the trials (26, 38.8%) were sponsored by a drug 
company, while the remaining (41, 61.2%) were promoted by an academic institution or a 
cooperative group. 
The details of each eligible publication are reported in Table 2 (studies conducted in 
early stages), in Table 3 (studies conducted in the first-line or maintenance setting) and in 
Table 4 (studies conducted in second- and further lines setting), respectively. 
 
 
3.2 Inclusion of QoL among study endpoints 
The inclusion of QoL among endpoints according to study characteristics is detailed in 
Table 5. In the whole series, QoL was a primary endpoint in 1 trial (1.5%), a secondary / 
exploratory endpoint in 21 trials (21.3%), while in the remaining 41 (61.2%) QoL was not 
listed at all among study endpoints. The proportion of trials without QoL as an endpoint was 
69%, 54.8% and 57.1% among papers published in journals with low, intermediate and high 
IF, respectively. QoL was not included among endpoints in a relevant proportion both in for-
profit trials (53.8%) and even more in non-profit trials (65.8%). 
8 
 
QoL was not listed among endpoints in 17 trials (85.0%) in adjuvant/neoadjuvant 
setting, in 13 trials (50.0%) in first line, and 11 trials (52.4%) in second and further lines.                                                        
Proportion of trials not including QoL among endpoints was similar over time: QoL was not 
listed in 26 trials (60.5%) publications between 2012 and 2015 vs. 15 trials (62.5%) between 
2016 and 2018. 
 
3.3 Presence of QoL results in the primary publication 
The presence of QoL results according to study characteristics is detailed in Table 6. 
Out of 26 primary publications of trials including QoL among endpoints, QoL results were not 
reported in 10 (38.5%). Due to the absence among study endpoints or to the lack of results in 
the publication, QoL results were available in 16 publications (23.9%), while QoL results were 
absent in the remaining 51 (76.1%): namely, 19 trials out of 20 (95.0%) in 
adjuvant/neoadjuvant setting, 18 trials out of 26 (69.2%) in first line and 14 trials out of 21 
(66.7%) in second and further lines. 
The proportion of publications without QoL results, due to absent endpoint or 
unpublished results, was 86.2%, 67.7% and 71.4% among papers published in journals with 
low, intermediate and high IF, respectively. QoL results were lacking in a relevant proportion 
both in publications of for-profit trials (73.1%) and non-profit trials (78.1%).  
Proportion of trials without available QoL results in primary publication was similar over 
time: QoL was lacking in 32 (74.4%) publications between 2012 and 2015 vs. 19 (79.2%) 
publications between 2016 and 2018. 
 
3.4 QoL secondary publications 
Overall, with a median follow-up of 45.3 months, 7 secondary QoL publications were 
found (the complete list of secondary publications is available in the Table 2 - 4). Median IF of 
the secondary QoL publications was 6.029 (interquartile range 5.548– 9.523, range 2.806 – 
36.421), compared to 18.038 (interquartile range 14.907—21.023, range 9.269—26.509) of 
the respective primary publication. For the 10 trials including QoL as an endpoint, but without 
any QoL result in the primary publication, probability of secondary publication was 0%, 33.3% 





3.5 QoL reporting according to study primary endpoint and study results 
21 trials (31.3%) had overall survival as primary endpoint, while the remaining 46 
(68.7%) had endpoints other than overall survival. Among the latter 46 trials, 30 (65.2%) did 
not include QoL as an endpoint, and among 16 trials including QoL as an endpoint, 6 did not 
report QoL results in primary publication. Overall, due to the absence of endpoint or 
unpublished results, QoL results were not reported in 36 (78.3%) publications of trials with a 
primary endpoint other than overall survival. 
According to authors’ conclusions, studies were divided into positive (32, 47.8%) and 
negative (35, 52.2%). Among 32 trials with positive results, 20 (62.5%) did not include QoL as 
an endpoint. Despite all trials with positive results including QoL as an endpoint reported QoL 
results in the primary publication (12 / 12, 100%), overall, due to absent endpoint, the majority 
of trials with positive results were lacking QoL results (20 / 32, 62.5%). Out of the 12 trials 
including QoL results, 5 trials reported a positive QoL result, while 7 trials reported negative 
QoL results. 
On the other hand, among 35 trials with negative results, 21 (60%) did not include QoL 
as an endpoint. Out of 14 negative trials including QoL among endpoints, 4 (28.6%) included 
QoL results in the primary publication and 5 (35.7%) reported QoL in a secondary publication: 
all these trials reported a negative QoL result. In the remaining 5 (35.7%) negative trials 
including QoL as an endpoint, results have not been published. 
In the investigated period, we identified 5 trials which prompted authorization for use in 
clinical practice by U.S. Food and Drug Administration (FDA) and European Medicines 
Agency (EMA), all of which were done in the setting of advanced disease. Three of these 
trials did not include QoL among endpoints.  
 
3.6 QoL methodology 
In 21 trials with available QoL results (including secondary publications), most common 
QoL tools were EORTC QLQ-C30 (14, 66.7%); EORTC colorectal cancer module (3, 14.3%); 
EQ5D (8, 38.1%); FACT-C (3, 14.3%) and other FACT tools (4, 19.0%).  
Common methods of analysis were mean scores over time (10, 47.6%), mean 
changes (6, 28.6%), time to deterioration (5, 23.8%) and proportion of responders or 
worsening patients (4, 19.0%). 
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Out of 26 trials with QoL as endpoint, 9 (34.6%) trials did not report details about 
compliance to QoL questionnaires, and 21 (80.7%) did not include any explicit statement 





This review of recently published randomized phase III trials conducted in CRC 
patients shows that QoL results are lacking, due to exclusion from study endpoints or 
absence of results, in a high proportion of publications. This deficiency is particularly relevant 
in trials of advanced disease, where attention to QoL should be necessarily higher. Of note, 
we found that QoL data were not available in 66.7% of the publications regarding second or 
further lines of treatment. Furthermore, our data show that methodology of QoL analysis is 
quite heterogeneous in terms of type of instruments, analysis and presentation of results. 
These results underline that, although QoL assessment in clinical trials is unanimously 
considered relevant, this principle is often not respected when clinical trials are designed and 
when results are analyzed and published.  
Similarly to our previous analyses, conducted in all solid tumors12 and in prostate 
cancer trials13, we collected the information about the presence of QoL among endpoints from 
the manuscript of the publication and from the study protocol, when the latter was available. 
However, we did not have access to study protocol for all the publications included in the 
analysis and, in some cases, we might have considered QoL apparently absent although it 
was actually included among endpoints. Consequently, the real prevalence of QoL could be 
higher than reported in our analysis. However, this limitation may reinforce our disappointing 
conclusions, because if a study included QoL among endpoints but this was completely 
neglected in the study publication, the importance attributed to QoL by the authors was de 
facto really marginal. 
Recent years have been characterized by the conduction and publication of many 
pivotal trials of new drugs and/or new combinations in CRC. However, inclusion of QoL 
among study endpoints results quite low (38.8% of publications considered) and this is 
reflected in the even lower proportion of trials with available QoL results (23.9% of primary 
publications), with a stable trend over the time period considered in the analysis (25.6% 
between 2012 and 2015 vs. 20.8% between 2016 and 2018). As a matter of fact, the high 
proportion of absent QoL results in the adjuvant setting could be not surprising, considering 
that the negative treatment impact - hopefully temporary - on QoL could be considered a 
“justified” risk, to obtain an improvement in the chance of a definitive cure. This could justify, 
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at least in part, the lower attention to QoL evaluation in early setting:  nearly all trials (95%) 
we analyzed did not include QoL among the endpoints, and this proportion in CRC is even 
higher than the result observed in all solid tumors12. However, absence of QoL is particularly 
relevant in the setting of metastatic patients, where only 31.9% of primary publications 
reported QoL results. Differently from trials conducted in early stages, the palliative setting is 
characterized by a relevant proportion of symptomatic patients and many treatments are 
characterized by a modest benefit in terms of PFS and OS. For these reasons, a complete 
evaluation of the balance between benefits and harms of treatments should necessarily 
include QoL evaluation. Furthermore, knowledge of QoL data could improve the information 
to patients, and facilitate clinical choice between alternative treatments, particularly if they 
show similar survival outcomes. 
For instance, in recent years, two different new drugs, namely regorafenib and 
trifluridine/tipiracil 4,5, have been tested in the third-line setting, showing a modest survival 
benefit, that led to approval by regulatory agencies and inclusion in clinical practice 
guidelines. However, while in the CORRECT study, testing the efficacy of regorafenib, a 
formal assessment of QoL was performed, in the RECOURSE study, testing TAS-102, QoL 
was not among study endpoints. In the latter case, the absence of QoL assessment has led 
study investigators to perform an indirect assessment of patients’ QoL, that is encumbered by 
several limitations, first of all the use of a non-validated instrument not based on patient-
reported outcomes14. 
Our literature research found that QoL results were presented in a secondary 
publication for seven trials. Although we recognize that splitting up QoL data in a separate 
publication from survival results seems to be an opportunity for a comprehensive way of 
reporting, probability of a secondary publication was only 50.0% even 5 years after first 
publication. Moreover, separate reporting of QoL results may reduce their value in clinical 
decision making, as clinicians less likely read or could be not aware of the successive 
papers15. Our findings corroborate previous observations, according to which most drugs 
enter the market without explicit evidence of benefit on QoL16. 
We also investigated the impact of QoL assessment in studies promoted by academic 
researchers and/or independent cooperative groups vs for-profit studies. Concordantly with 
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our previous results in all solid tumors, both for-profit and, even more, non-profit trials did not 
include QoL among endpoints in a considerable percentage (73.1% for profit- trials and 
78.1% in non-profit trials). In our view, this result is particularly disappointing, considering that 
academic trials, if really aiming to optimize treatment choices in clinical practice, should be 
characterized by higher attention to QoL. 
Several methodological issues can be associated with the adoption of QoL among the 
endpoints of a clinical trial. For example, the choice of the correct QoL questionnaire and of 
the proper timing of questionnaires administration, the method of analysis and description of 
results, and the statistical management of missing data may be particularly challenging. CRC, 
especially in patients who have already received multiple lines of treatment, is exposed to a 
non-negligible proportion of early deterioration and treatment withdrawal compared to other 
tumors characterized by a better prognosis (e.g. breast cancer or prostate cancer). In these 
clinically challenging scenarios, missing data can represent a methodological problem, and 
we suppose that many researchers could consider this issue as a barrier to adoption of QoL 
questionnaires. While data missing at baseline are substantially related to defects in the 
quality of study procedures, missing data at later time points may be frequently related to 
treatment toxicities, tumor progression and/or symptomatic worsening, with difficulty in 
completing questionnaires. This aspect could introduce possible selection bias (patients who 
complete questionnaires feel better than those who do not complete) and could lead to 
misleading results regarding QoL, which is particularly relevant in patients with advanced and 
progressive disease. Unfortunately, we found that only a minority of publications clarified 
methods of management of missing data in QoL analysis.  
As well as for other solid tumors, several validated QoL tools are currently available for 
trials conducted in CRC cancer, each one with its strengths and weaknesses. As expected, 
we found differences in their adoption among trials. The most common instrument used for 
QoL assessment was the EORTC Quality of Life Questionnaire C30 (66.7% of trials with 
available QoL details), supplemented in few cases by the CRC-specific module. However, 
some studies used other types of QoL assessments.  
Not surprisingly, similarly to what we described in other settings13, we found a 
significant heterogeneity in the methods used for the analysis and presentation of QoL 
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results. As expected, we found that description of mean scores or mean changes from 
baseline at different time points was commonly used to summarize QoL results (47.6% and 
28.6% of trials with available QoL results, respectively). This method allows a simple 
graphical and numerical representation of results, it is familiar to most readers and it is widely 
accepted to compare QoL trajectory among different study arms. However, this method is 
weak in capturing a potentially relevant heterogeneity in the QoL response experienced by 
individual patients17. From this point of view, analysis of responders (proportion of subjects 
with improved or stable or worse score, compared to baseline) in each specific QoL domain 
gives a useful complementary information, but our analysis showed that it is adopted only in a 
minority of studies (19%). In addition, many studies describe QoL results with a particular 
emphasis on the early phase of treatment (that is of course useful to reassure about the 
absence of a negative impact of treatment toxicity on patients’ status), but only a minority of 
studies focus on QoL description at the time of instrumental progression and treatment failure. 
Curves describing the time to deterioration of global QoL or specific symptoms are particularly 
useful in describing the real efficacy of experimental treatment in delaying symptomatic 
worsening of disease. Unfortunately, we found this kind of analysis only in 23.8% of the trials 
analyzed. 
Of course, no single method of analysis and presentation can assure an exhaustive 
description of QoL results. Moreover, even in those cases where more methods are planned 
in the study protocol,  the presentation of results is often suboptimal, as the space dedicated 
to QoL is often marginal12.This appears rather surprising, because the limitations in article 
length could be easily exceeded by the possibility to integrate the main article with online 
supplement and appendix materials. 
In conclusion, our review of trials conducted in colorectal cancer and published in 
recent years shows that the inclusion of QoL among study endpoints and the timely and 
complete reporting of QoL results are definitely suboptimal. The heterogeneity in the choice of 
instruments, timing, modality and presentation of analysis and presentation of results make 




Figures and tables 
 
Figure 1. Kaplan-Meier curves of time to secondary publication with quality of life (QoL) 
results, for trials including QoL as a secondary / exploratory endpoint, but without any QoL 












Table 1. Characteristics of the 67 primary publications included in the analysis. 
 Number of publications (%) 
Year of primary manuscript   
2012  9 13,4% 
2013 11 16,4% 
2014 7 10,5% 
2015 16 23,9% 
2016 9 13,4% 
2017 4 6,0% 
2018 11 16,4% 
Primary manuscript journal   
Annals of Oncology 18 26,8% 
British Journal of Cancer 2 3,0% 
European Journal of Cancer 4 6,0% 
JAMA  3 4,5% 
Journal of Clinical Oncology 14 20,9% 
Journal of National Cancer Institute 2 3,0% 
Lancet 2 3,0% 
Lancet Oncology 20 29,8% 
New England Journal of Medicine 2 3,0% 
Sources of funding   
Profit 26 38,8% 
Non-profit 41 61,2% 
Setting of disease   
Adjuvant/neoadjuvant setting 20 29,9% 
First-line or maintenance setting 26 38,8% 
Second and further lines 21 31,3% 
Study design   
Superiority 53 79,1% 
Non-inferiority 14 20,9% 
Masking   
Open label 52 77,6% 
Blinded 15 22,4% 
Countries involved   
Single country 33 49,3% 
2 or more countries 34 50,7% 
Type of experimental therapy*   
Chemotherapy +/- other 52 77,6% 
Targeted therapy +/- other 40 59,7% 
Primary endpoint   
Overall survival  21 31,3% 
Other 46 68,7% 
Study result   
Positive  32 47,8% 
Negative 35 52,2% 
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5-FU: 5-Fluorouracil; AUC: Area Under the Curve; CAPOX: Capecitabine-Oxaliplatin; CRT: Chemo-Radiotherapy; DFS: Disease Free Survival; EORTC 
QLQ-C30: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30; EORTC QLQ-CR29: European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29; EORTC QLQ-CR38: European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 38; EQ5D: Euro Qol five-dimensional questionnaire; FACT-
GOG/Ntx: FACT - Gynecologic Oncology Group/Neurotoxicity; FOLFIRI: 5FU-Leucovorin-Irinotecan; FOLFOX: 5FU-Leucovorin-Oxaliplatin; FUP: Follow 
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* declared in the protocol but results not present in the work 
5-FU: 5-Fluorouracil; CAPOX: Capecitabine-Oxaliplatin; EQ5D: Euro Qol five-dimensional questionnaire; EORTC QLQ-C30: European Organization for 
Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30; EORTC QLQ-CR29: European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire-Colorectal Cancer 29; FACT-C: Functional Assessment of Cancer Therapy- Colorectal cancer;  FACT-GOG/Ntx: 
FACT-Gynecologic Oncology Group/Neurotoxicity; FLOX: 5FU- Leucovorin- Oxaliplatin; FOLFIRI: 5FU-Leucovorin-Irinotecan; FOLFOX: 5FU-Leucovorin-
Oxaliplatin; FOLFOXIRI: 5FU-Leucovorin-Irinotecan-Oxaliplatin; FUP: Follow up; mFOLFOX: modified FOLFOX; n.s.: not specified; OS: overall survival; 
PFS: progression-free survival; QoL VAS: QoL-Visual Analogue Scale; QoL: Quality of Life; SIRT: selective internal radiotherapy; TCD: Tumor control 






























































- - - - - - - - 
Grothey 

















































































































- n.s. n.s. Absen
t 
n.s. n.s. n.s. n.s. 
Seymou





















































































































































































- - - - - - - - 










































































- - - - - - - - 
Mayer 












































- - - - - - - - 
Sclafani 































- n.s. n.s. Absen
t 














m2   
 
Tabern





























































- - - - - - - - 
Cascinu 































- - - - - - - - 
Hickish 

































































- - - - - - - - 







































- - - - - - - - 
Van 
Cutsem 

















- n.s. n.s. Absen
t 
n.s. n.s. n.s. n.s. 
* We have considered these studies as separated because two different publications were issued. 
5-FU: 5-Fluorouracil; AUC: Area Under the Curve; CAPOX: Capecitabine-Oxaliplatin; EORTC QLQ-C30: European Organization for Research and 
Treatment of Cancer – Quality of Life Questionnaire – Core 30; EORTC: European Organization for Research and Treatment of Cancer; EQ5D: 
EuroQol five-dimensional questionnaire; FACT: Functional Assessment of Cancer Therapy; FOLFIRI: 5FU-Leucovorin-Irinotecan; FOLFOX: 5FU-
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Table 5. Inclusion of health-related quality of life among study endpoints according to characteristics 
of study and publication. 








QoL not included 
among  
Endpoints 
Whole series 67 1 (1.5%) 25 (37.3%) 41 (61.2%) 
Year of primary 
manuscript 
    
2012  9 - 4 (44.4%) 5 (55.6%) 
2013 11 - 5 (45.5%) 6 (54.5%) 
2014 7 - 1 (14.3%) 6 (85.7%) 
2015 16 - 7 (43.8%) 9 (56.2%) 
2016 9 - 3 (33.3%) 6 (66.7%) 
2017 4 1 (25.0%) 1 (25.0%) 2 (50.0%) 
2018 11 - 4 (36.4%) 7 (63.6%) 
Journal Impact Factor     
Low (<15) 29 1 (3.4%) 8 (27.6%) 20 (69.0%) 
Intermediate (15-
30) 
31 - 14 (45.2%) 17 (54.8%) 
High (>30) 7 - 3 (42.9%) 4 (57.1%) 
Sources of funding     
Profit 26 1 (3.8%) 11 (42.3%) 14 (53.9%) 
Non-profit 41 - 14 (34.1%) 27 (65.9%) 
Setting of disease     
Adjuvant/neoadjuva
nt setting 
20 - 3 (15.0%) 17 (85.0%) 
First-line or 
maintenance setting 
26 - 13 (50.0%) 13 (50.0%) 
Second and further 
lines 
21 1 (4.8%) 9 (42.8%) 11 (52.4%)  
Study design     
Superiority 53 1 (1.9%) 18 (34.0%) 34 (64.1%) 
Non-inferiority 14 - 7 (50%) 7 (50.0%) 
Masking     
Open label 52 - 17 (32.7%) 35 (67.3%) 
Blinded 15 1 (6.7%) 8 (53.3%) 6 (40%) 
Type of experimental therapy*    
Chemotherapy +/- 
other 
52 - 17 (32.7%) 35 (67.3%) 
Targeted therapy 
+/- other 
40 1 (2.5%) 18 (45.0%) 21 (52.5%) 
Primary endpoint     
Overall survival  21 - 10 (47.6%) 11 (52.4%) 
Other 46 1 (2.2%) 15 (32.6%) 30 (65.2%) 
Study result     
Positive  32 1 (3.1%) 11 (34.4%) 20 (62.5%) 
Negative 35 - 14 (40.0%) 21 (60.0%) 




Table 6. Details about health-related quality of life in trials 
 Number of 
publications 
QoL results  
available in primary 
publication 
QoL results 
absent in primary 
publication 
Whole series 67 16 (23.9%) 51 (76.1%) 
Year of primary manuscript    
2012  9 2 (22.2%) 7 (77.8%) 
2013 11 3 (27.3%) 8 (72.7%) 
2014 7 1 (14.3%) 6 (85.7%) 
2015 16 5 (31.2%) 11 (68.8%) 
2016 9 1 (11.1%) 8 (88.9%) 
2017 4 1 (25.0%) 3 (75.0%) 
2018 11 3 (27.3%) 8 (72.7%) 
Journal Impact Factor    
Low (<15) 29 4 (13.8%) 25 (86.2%) 
Intermediate (15-30) 31 10 (32.3%) 21 (67.7%) 
High (>30) 7 2 (28.6%) 5 (71.4%) 
Sources of funding    
Profit 26 7 (26.9%) 19 (73.1%) 
Non-profit 41 9 (21.9%) 32 (78.1%) 
Setting of disease    
Adjuvant/neoadjuvant setting 20 1 (5.0%) 19 (95.0%) 
First-line or maintenance setting 26 8 (30.8%) 18 (69.2%) 
Second and further lines 21 7 (33.3%) 14 (66.7%) 
Study design    
Superiority 53 10 (18.9%) 43 (81.1%) 
Non-inferiority 14 6 (42.9%) 8 (57.1%) 
Masking    
Open label 52 10 (19.2%) 42 (80.8%) 
Blinded 15 6 (40.0%) 9 (60.0%) 
Type of experimental therapy*    
Chemotherapy +/- other 52 8 (15.4%) 44 (84.6%) 
Targeted therapy +/- other 40 13 (32.5%) 27 (67.5%) 
Primary endpoint    
Overall survival  21 6 (28.6%) 15 (71.4%) 
Other 46 10 (21.7%) 36 (78.3%) 
Study result    
Positive  32 12 (37.5%) 20 (62.5%) 
Negative 35 4 (11.4%) 31 (88.6%) 
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Background: In this study, our aim was to describe QoL prevalence and heterogeneity in 
QoL reporting in colorectal cancer phase III trials. 
Methods: We included all phase III trials evaluating anticancer drugs in colorectal cancer 
patients published between 2012 and 2018 by 11 major journals.  
Results: Out of the 67 publications identified, in 41 (61.2%) QoL was not listed among 
endpoints. Out of 26 primary publications of trials including QoL among endpoints, QoL 
results were not reported in 10 (38.5%). Overall, no QoL data were available in 51/67 (76.1%) 
primary publications.. In particular, in the metastatic setting, QoL data were not available in 
12/18 (66.7%) trials with primary endpoint overall survival, and in 20/29 (69.0%) trials with 
other primary endpoints.  
Conclusions: QoL was absent in a high proportion of recently published phase III trials in 
colorectal cancer, even in trials of second or further lines, where attention to QoL should be 
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Colorectal cancer (CRC) represents the third most common cancer affecting both men 
and women worldwide1. Although metastatic CRC (mCRC) remains a highly lethal disease, 
recent advances in the outcome of these patients have been achieved. This prognostic 
improvement could be attributed to several factors, including the availability of new drugs 
and/or new combinations, with a median overall survival (mOS) considerably increased from 
12 months in the 5-fluorouracil (5-FU)-based chemotherapy era to approximately 30 months 
observed in recent clinical trials2,3. 
Notwithstanding the increased anti-tumoral activity and efficacy of systemic treatments, 
the impact of drug toxicity, that could negatively affect patients’ quality of life (QoL), should 
not be forgotten, particularly in those clinical settings characterized by a lower limited life 
expectancy and a more delicate balance between benefits and harms of treatment. In the 
latter settings, uncertainty could remains concerning the net clinical benefit, especially for 
patients with chemo-refractory mCRC treated in and beyond third-line setting. In these 
patients, several drugs recently approved for use in clinical practice, like regorafenib and 
TAS-102, produce a modest survival benefit, with not negligible toxicity issues4,5. Therefore, 
particularly in this scenario, an integrated analysis of “cost-benefit” ratio for the patient should 
become mandatory6, as well as the evaluation of patients’ experience with patient reported 
outcomes (PROs). 
PROs, which are outcomes assessed directly by the patient7, may produce a different 
patients’ perspective on the disease and treatment received, complementing the conventional 
reporting of anti-tumor efficacy data and the physician-based description of adverse events 8. 
Health-related quality of life (HRQoL) is a specific type of PRO which evaluates the patient’s 
perspective “of the impact of his disease and its treatment(s) on his daily life, physical, 
psychological and social functioning and well-being”7. In dedicated documents, European 
Medicines Agency (EMA) and Food and Drug Administration (FDA) emphasized the 
importance of the impact of treatments on health-related quality of life in everyday life7,9. 
These aspects are crucial for the evaluation of the clinical benefits of new drugs. Indeed, 
PROs provide data on patient's QoL, symptoms, treatment adherence or satisfaction with 
care by including any informations directly reported by the patient himself/herself on his/her 
perception of the disease and its treatment. PROs try to capture a personal perspective, that 
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may vary from person to person, using well-established methods. PROs should be more 
widely used to complement the range of traditional indicators of efficacy in oncology and 
provide information regarding both positive and negative patient experiences. Moreover, in 
2015, both American Society of Clinical Oncology (ASCO) and the European Society of 
Medical Oncology (ESMO) proposed frameworks to quantify the benefit of oncology 
medications, and QoL is included in both instruments10,11. 
In a previous systematic review, not specifically focused on CRC, we showed that QoL 
was not included among endpoints in a high proportion (210 of the 446 publications analyzed, 
47%) of oncology phase III randomized trials published by major journals between 2012 and 
2016. In addition,   even when QoL was included among study endpoints, we found that QoL 
results were significantly underreported and often affected by a significant delay in 
publication12.  
Aim of this systematic review is to describe QoL prevalence as an endpoint in 
randomized phase III trials testing anticancer drugs in colorectal cancer patients, published 
between 2012 and 2018. In addition, we described the underreporting of QoL results and 






Articles published by 11 major scientific journals, previouslyalready  selected for theour 
original analysis in all solid tumors as the journals where oncology randomized controlled 
trials are usually published 12,  were retrieved for this analysisupdate spcecifically focused on 
colorectal cancer trials.: Nnamely, our search included 3 general medical journals (New 
England Journal of Medicine, Lancet, JAMA) and 8 oncology journals (Lancet Oncology, 
Journal of Clinical Oncology, JAMA Oncology, Journal of the National Cancer Institute, 
Annals of Oncology, European Journal of Cancer, British Journal of Cancer, Cancer). With 
the aim to identify primary publications of randomized phase III trials testing anticancer drugs 
in patients with solid tumors, all issues of the aformentioned journals published between 
January 2012 and December 2018 were hand-searched. The original analysis12,  limited to 
papers published between 2012 and 2016, has been updated for the present analysis, with 
the addition of articles on CRC published in 2017 and 2018.  
Trials testing non-pharmacologic interventions were excluded from the analysis. Both 
trials conducted in early stages of disease (e.g., adjuvant chemotherapy, neo-adjuvant 
chemo-radiotherapy) and trials conducted in advanced / metastatic setting were included, 
while trials testing prevention strategies were excluded.  
To collect data from each selected paper, the same dedicated case report form used 
for the previous analysis12 was adopted, and the electronic database, with one record for 
each paper, was updated. For each trial, information about publication (journal, year, first 
author, date of definitive issue and ahead-of-print publication, availability of online 
supplemental material and/or study protocol) was collected. Impact factor (IF), corresponding 
to the year of each publication, was retrieved from the Journal of Citation Reports, and 
publications were divided into 3 categories according to IF: low (<15), intermediate (15-30), 
high (>30). Information recorded about the clinical trial included: sponsorship (for-profit vs. 
non-profit), study design (open-label vs. blinded; superiority vs. non-inferiority), details of 
treatment of both experimental and control arms, disease setting. Articles were divided in 3 
categories: (i) adjuvant or neoadjuvant treatment in early stages; (ii) first-line treatment for 
metastatic disease; (iii) second and/or further lines of treatment for metastatic disease. 
Similarly to our previous analysis, trials were classified as for-profit when sponsored by the 
drug company and as non-profit when sponsored by an academic institution or a cooperative 
group, even if receiving drug supply and/or economic support from one or more drug 
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companies (when not explicitedexplicated in the publication, details about the study 
sponsorship were retrieved from ClinicalTrials.gov study record, if available). Experimental 
treatments were classified into 2 main groups (that were not mutually exclusive): 
chemotherapy +/- other drugs; targeted agents +/- other drugs. According to study results in 
terms of primary endpoint, clinical trials were classified into positive or negative.  
Information about study endpoints (both primary and secondary, tertiary or exploratory) 
was derived from the Methods section of the publication and/or from the study protocol (when 
available as online supplementary material). When QoL was not listed among endpoints in 
the paper and study protocol was not available, QoL was considered as “apparently absent”, 
except when QoL results were actually presented in the Results section or in a secondary 
publication: in the latter case, QoL was included de facto among endpoints. For all records, 
secondary QoL publications were searched in PubMed, by using the name of the drug(s) 
and/or the name of authors of the primary publication and/or the study acronym / code, when 
available. Time to secondary QoL publication was calculated according to Kaplan-Meier 
method, from the date of primary definitive publication to the date of secondary QoL definitive 
publication, if existing, or to the date of last PubMed check (February 15th, 2019).  
Details of QoL methodology (type of QoL tools adopted, type of statistical analysis and 
presentation of results) were collected. As for type of statistical analysis, several non-mutually 
exclusive categories were identified: mean scores at different time points, mean changes from 
baseline, proportion of responding patients, time to deterioration. Among details of QoL 
methodology, we verified whether statistical approaches for dealing with missing data were 
explicitly stated in the paper and whether data about compliance to QoL questionnaires were 
reported in the publication.  







3.1 Study characteristics 
Overall, 67 eligible publications were identified. The main characteristics of the eligible 
publications are reported in Table 1 (the complete list is reported in the table 2 - 4).  
The three most represented journals were Lancet Oncology (20 papers, 29.9%), 
Annals of Oncology (18 papers, 26.9%) and Journal of Clinical Oncology (14 papers, 20.9%). 
Median IF of the eligible publications was 18.038 (interquartile range 11.612—26.303, 
range 4.819—59.558).  
The majority of trials (47, 70.1%) were conducted in patients with advanced/metastatic 
disease, but studies are well distributed among the 3 setting categories that we defined for 
classification: adjuvant/neoadjuvant setting (20, 29.9%), first-line or maintenance setting (26, 
38.8%) and second and further lines setting (21, 31.3%). Experimental treatment was 
chemotherapy ± other drugs in 52 trials (77,6%) and targeted therapy ± other drugs in 40 
trials (59,7%). More than one-third of the trials (26, 38.8%) were sponsored by a drug 
company, while the remaining (41, 61.2%) were promoted by an academic institution or a 
cooperative group. 
The details of each eligible publication are reported in Table 2 (studies conducted in 
early stages), in Table 3 (studies conducted in the first-line or maintenance setting) and in 
Table 4 (studies conducted in second- and further lines setting), respectively. 
 
 
3.2 Inclusion of QoL among study endpoints 
The inclusion of QoL among endpoints according to study characteristics is detailed in 
Table 5. In the whole series, QoL was a primary endpoint in 1 trial (1.5%), a secondary / 
exploratory endpoint in 21 trials (21.3%), while in the remaining 41 (61.2%) QoL was not 
listed at all among study endpoints. The proportion of trials without QoL as an endpoint was 
69%, 54.8% and 57.1% among papers published in journals with low, intermediate and high 
IF, respectively. QoL was not included among endpoints in a relevant proportion both in for-
profit trials (53.8%) and even more in non-profit trials (65.8%). 
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QoL was not listed among endpoints in 17 trials (85.0%) in adjuvant/neoadjuvant 
setting, in 13 trials (50.0%) in first line, and 11 trials (52.4%) in second and further lines.                                                        
Proportion of trials not including QoL among endpoints was similar over time: QoL was not 
listed in 26 trials (60.5%) publications between 2012 and 2015 vs. 15 trials (62.5%) between 
2016 and 2018. 
 
3.3 Presence of QoL results in the primary publication 
The presence of QoL results according to study characteristics is detailed in Table 6. 
Out of 26 primary publications of trials including QoL among endpoints, QoL results were not 
reported in 10 (38.5%). Due to the absence among study endpoints or to the lack of results in 
the publication, QoL results were available in 16 publications (23.9%), while QoL results were 
absent in the remaining 51 (76.1%): namely, 19 trials out of 20 (95.0%) in 
adjuvant/neoadjuvant setting, 18 trials out of 26 (69.2%) in first line and 14 trials out of 21 
(66.7%) in second and further lines. 
The proportion of publications without QoL results, due to absent endpoint or 
unpublished results, was 86.2%, 67.7% and 71.4% among papers published in journals with 
low, intermediate and high IF, respectively. QoL results were lacking in a relevant proportion 
both in publications of for-profit trials (73.1%) and non-profit trials (78.1%).  
Proportion of trials without available QoL results in primary publication was similar over 
time: QoL was lacking in 32 (74.4%) publications between 2012 and 2015 vs. 19 (79.2%) 
publications between 2016 and 2018. 
 
3.4 QoL secondary publications 
Overall, with a median follow-up of 45.3 months, 7 secondary QoL publications were 
found (the complete list of secondary publications is available in the Table 2 - 4). Median IF of 
the secondary QoL publications was 6.029 (interquartile range 5.548– 9.523, range 2.806 – 
36.421), compared to 18.038 (interquartile range 14.907—21.023, range 9.269—26.509) of 
the respective primary publication. For the 10 trials including QoL as an endpoint, but without 
any QoL result in the primary publication, probability of secondary publication was 0%, 33.3% 





3.5 QoL reporting according to study primary endpoint and study results 
21 trials (31.3%) had overall survival as primary endpoint, while the remaining 46 
(68.7%) had endpoints other than overall survival. Among the latter 46 trials, 30 (65.2%) did 
not include QoL as an endpoint, and among 16 trials including QoL as an endpoint, 6 did not 
report QoL results in primary publication. Overall, due to the absence of endpoint or 
unpublished results, QoL results were not reported in 36 (78.3%) publications of trials with a 
primary endpoint other than overall survival. 
According to authors’ conclusions, studies were divided into positive (32, 47.8%) and 
negative (35, 52.2%). Among 32 trials with positive results, 20 (62.5%) did not include QoL as 
an endpoint. Despite all trials with positive results including QoL as an endpoint reported QoL 
results in the primary publication (12 / 12, 100%), overall, due to absent endpoint, the majority 
of trials with positive results were lacking QoL results (20 / 32, 62.5%). Out of the 12 trials 
withincluding QoL results, 5 trials reported a positive QoL result, while 7 trials reported 
negative QoL results. 
On the other hand, among 35 trials with negative results, 21 (60%) did not include QoL 
as an endpoint. Out of 14 negative trials withincluding QoL among endpoints, 4 (28.6%) 
included QoL results in the primary publication and 5 (35.7%) reported QoL in a secondary 
publication: all these trials reported a negative QoL result. In the remaining 5 (35.7%) 
negative trials including QoL as an endpoint, results have not been published. 
In the investigated period, we identified 5 trials which prompted authorization for use in 
clinical practice by U.S. Food and Drug Administration (FDA) and European Medicines 
Agency (EMA), all of which were done in the setting of advanced disease. Three of these 
trials did not include QoL among endpoints.  
 
3.6 QoL methodology 
In 21 trials with available QoL results (including secondary publications), most common 
QoL tools were EORTC QLQ-C30 (14, 66.7%); EORTC colorectal cancer module (3, 14.3%); 
EQ5D (8, 38.1%); FACT-C (3, 14.3%) and other FACT tools (4, 19.0%).  
Common methods of analysis were mean scores over time (10, 47.6%), mean 
changes (6, 28.6%), time to deterioration (5, 23.8%) and proportion of responders or 
worsening patients (4, 19.0%). 
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Out of 26 trials with QoL as endpoint, 9 (34.6%) trials did not report details about 
compliance to QoL questionnaires, and 21 (80.7%) did not include any explicit statement 





This review of recently published randomized phase III trials conducted in CRC 
patients shows that QoL results are lacking, due to exclusion from study endpoints or 
absence of results, in a high proportion of publications. This deficiency is particularly relevant 
in trials of advanced disease, where attention to QoL should be necessarily higher. Of note, 
we found that QoL data were not available in 66.7% of the publications regarding second or 
further lines of treatment. Furthermore, our data show that methodology of QoL analysis is 
quite heterogeneous in terms of type of instruments, analysis and presentation of results. 
These results underline that, although QoL assessment in clinical trials is unanimously 
considered relevant, this principle is often not respected when clinical trials are designed and 
when results are analyzed and published.  
Similarly to our previous analyses, conducted in all solid tumors12 and in prostate 
cancer trials13, we collected the information about the presence of QoL among endpoints from 
the manuscript of the publication and from the study protocol, when the latter was available. 
However, we did not have access to study protocol for all the publications included in the 
analysis and, in some cases, we might have considered QoL apparently absent although it 
was actually included among endpoints. Consequently, the real prevalence of QoL could be 
higher than reported in our analysis. However, this limitation may reinforce our disappointing 
conclusions, because if a study included QoL among endpoints but this was completely 
neglected in the study publication, the importance attributed to QoL by the authors was de 
facto really marginal. 
Recent years have been characterized by the conduction and publication of many 
pivotal trials of new drugs and/or new combinations in CRC. However, inclusion of QoL 
among study endpoints results quite low (38.8% of publications considered) and this is 
reflected in the even lower proportion of trials with available QoL results (23.9% of primary 
publications), with a stable trend over the time period considered in the analysis (25.6% 
between 2012 and 2015 vs. 20.8% between 2016 and 2018). As a matter of fact, the high 
proportion of absent QoL results in the adjuvant setting could be not surprising, considering 
that the negative treatment impact - hopefully temporary - on QoL could be considered a 
“justified” risk, to obtain an improvement in the chance of a definitive cure. This could justify, 
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at least in part, the lower attention to QoL evaluation in early setting:  nearly all trials (95%) 
we analyzed did not include QoL among the endpoints, and this proportion in CRC is even 
higher than the result observed in all solid tumors12. However, absence of QoL is particularly 
relevant in the setting of metastatic patients, where only 31.9% of primary publications 
reported QoL results. Differently from trials conducted in early stages, the palliative setting is 
characterized by a relevant proportion of symptomatic patients and many treatments are 
characterized by a modest benefit in terms of PFS and OS. For these reasons, a complete 
evaluation of the balance between benefits and harms of treatments should necessarily 
include QoL evaluation. Furthermore, knowledge of QoL data could improve the information 
to patients, and facilitate clinical choice between alternative treatments, particularly if they 
show similar survival outcomes. 
For instance, in recent years, two different new drugs, namely regorafenib and 
trifluridine/tipiracil 4,5, have been tested in the third-line setting, showing a modest survival 
benefit, that led to approval by regulatory agencies and inclusion in clinical practice 
guidelines. However, while in the CORRECT study, testing the efficacy of regorafenib, a 
formal assessment of QoL was performed, in the RECOURSE study, testing TAS-102, QoL 
was not among study endpoints. In the latter case, the absence of QoL assessment has led 
study investigators to perform an indirect assessment of patients’ QoL, that is encumbered by 
several limitations, first of all the use of a non-validated instrument not based on patient-
reported outcomes14. 
Our literature research found that QoL results were presented in a secondary 
publication for seven trials. Although we recognize that splitting up QoL data in a separate 
publication from survival results seems to be an opportunity for a comprehensive way of 
reporting, probability of a secondary publication was only 50.0% even 5 years after first 
publication. Moreover, separate reporting of QoL results may reduce their value in clinical 
decision making, as clinicians less likely read or could be not aware of the successive 
papers15. Our findings corroborate previous observations, according to which most drugs 
enter the market without explicit evidence of benefit on QoL16. 
We also investigated the impact of QoL assessment in studies promoted by academic 
researchers and/or independent cooperative groups vs for-profit studies. Concordantly with 
13 
 
our previous results in all solid tumors, both for-profit and, even more, non-profit trials did not 
include QoL among endpoints in a considerable percentage (73.1% for profit- trials and 
78.1% in non-profit trials). In our view, this result is particularly disappointing, considering that 
academic trials, if really aiming to optimize treatment choices in clinical practice, should be 
characterized by higher attention to QoL. 
Several methodological issues can be associated with the adoption of QoL among the 
endpoints of a clinical trial. For example, the choice of the correct QoL questionnaire and of 
the proper timing of questionnaires administration, the method of analysis and description of 
results, and the statistical management of missing data may be particularly challenging. CRC, 
especially in patients who have already received multiple lines of treatment, is exposed to a 
non negligiblenon-negligible proportion of early deterioration and treatment withdrawal 
compared to other tumors characterized by a better prognosis (e.g. breast cancer or prostate 
cancer). In these clinically challenging scenarios, missing data can represent a 
methodological problem, and we suppose that many researchers could consider this issue as 
a barrier to adoption of QoL questionnaires. While data missing at baseline are substantially 
related to defects in the quality of study procedures, missing data at later time points may be 
frequently related to treatment toxicities, tumor progression and/or symptomatic worsening, 
with difficulty in completing questionnaires. This aspect could introduce possible selection 
bias (patients who complete questionnaires feel better than those who do not complete) and 
could lead to misleading results regarding QoL, which is particularly relevant in patients with 
advanced and progressive disease. Unfortunately, we found that only a minority of 
publications clarified methods of management of missing data in QoL analysis.  
As well as for other solid tumors, several validated QoL tools are currently available for 
trials conducted in CRC cancer, each one with its strengths and weaknesses. As expected, 
we found differences in their adoption among trials. The most common instrument used for 
QoL assessment was the EORTC Quality of Life Questionnaire C30 (66.7% of trials with 
available QoL details), supplemented in few cases by the CRC-specific module. However, 
some studies used other types of QoL assessments.  
Not surprisingly, similarly to what we described in other settings13, we found a 
significant heterogeneity in the methods used for the analysis and presentation of QoL 
14 
 
results. As expected, we found that description of mean scores or mean changes from 
baseline at different time points was commonly used to summarize QoL results (47.6% and 
28.6% of trials with available QoL results, respectively). This method allows a simple 
graphical and numerical representation of results, it is familiar to most readers and it is widely 
accepted to compare QoL trajectory among different study arms. However, this method is 
weak in capturing a potentially relevant heterogeneity in the QoL response experienced by 
individual patients17. From this point of view, analysis of responders (proportion of subjects 
with improved or stable or worse score, compared to baseline) in each specific QoL domain 
gives a useful complementary information, but our analysis showed that it is adopted only in a 
minority of studies (19%). In addition, many studies describe QoL results with a particular 
emphasis on the early phase of treatment (that is of course useful to reassure about the 
absence of a negative impact of treatment toxicity on patients’ status), but only a minority of 
studies focus on QoL description at the time of instrumental progression and treatment failure. 
Curves describing the time to deterioration of global QoL or specific symptoms are particularly 
useful in describing the real efficacy of experimental treatment in delaying symptomatic 
worsening of disease. Unfortunately, we found this kind of analysis only in 23.8% of the trials 
analyzed. 
Of course, no single method of analysis and presentation can assure an exhaustive 
description of QoL results. Moreover, even in those cases where more methods are planned 
in the study protocol,  the presentation of results is often suboptimal, as the space dedicated 
to QoL is often marginal12.This appears rather surprising, because the limitations in article 
length could be easily exceeded by the possibility to integrate the main article with online 
supplement and appendix materials. 
In conclusion, our review of trials conducted in colorectal cancer and published in 
recent years shows that the inclusion of QoL among study endpoints and the timely and 
complete reporting of QoL results are definitely suboptimal. The heterogeneity in the choice of 
instruments, timing, modality and presentation of analysis and presentation of results make 
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Figure 1. Kaplan-Meier curves of time to secondary publication with quality of life (QoL) 
results, for trials including QoL as a secondary / exploratory endpoint, but without any QoL 












Table 1. Characteristics of the 67 primary publications included in the analysis. 
 Number of publications (%) 
Year of primary manuscript   
2012  9 13,4% 
2013 11 16,4% 
2014 7 10,5% 
2015 16 23,9% 
2016 9 13,4% 
2017 4 6,0% 
2018 11 16,4% 
Primary manuscript journal   
Annals of Oncology 18 26,8% 
British Journal of Cancer 2 3,0% 
European Journal of Cancer 4 6,0% 
JAMA  3 4,5% 
Journal of Clinical Oncology 14 20,9% 
Journal of National Cancer Institute 2 3,0% 
Lancet 2 3,0% 
Lancet Oncology 20 29,8% 
New England Journal of Medicine 2 3,0% 
Sources of funding   
Profit 26 38,8% 
Non-profit 41 61,2% 
Setting of disease   
Adjuvant/neoadjuvant setting 20 29,9% 
First-line or maintenance setting 26 38,8% 
Second and further lines 21 31,3% 
Study design   
Superiority 53 79,1% 
Non-inferiority 14 20,9% 
Masking   
Open label 52 77,6% 
Blinded 15 22,4% 
Countries involved   
Single country 33 49,3% 
2 or more countries 34 50,7% 
Type of experimental therapy*   
Chemotherapy +/- other 52 77,6% 
Targeted therapy +/- other 40 59,7% 
Primary endpoint   
Overall survival  21 31,3% 
Other 46 68,7% 
Study result   
Positive  32 47,8% 
Negative 35 52,2% 
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5-FU: 5-Fluorouracil; AUC: Area Under the Curve; CAPOX: Capecitabine-Oxaliplatin; CRT: Chemo-Radiotherapy; DFS: Disease Free Survival; EORTC 
QLQ-C30: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30; EORTC QLQ-CR29: European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29; EORTC QLQ-CR38: European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 38; EQ5D: Euro Qol five-dimensional questionnaire; FACT-
GOG/Ntx: FACT - Gynecologic Oncology Group/Neurotoxicity; FOLFIRI: 5FU-Leucovorin-Irinotecan; FOLFOX: 5FU-Leucovorin-Oxaliplatin; FUP: Follow 




























































































































































































































- n.s. n.s. Absen
t 
n.s. n.s. n.s. n.s. 
Cunnin
gham 
D et al, 
201343 
Metas









- - - - - - - - 
Johnss



















- - - - - - - - 
Yamad




tatic   
- First-
line 







































V et al, 
201447 
Metas












- - - - - - - - 
Loupak












 PFS2 Positive Abse
nt 
- - - - - - - - 
Primro





























































































































































































































tatic   
- First-
line 



































































































































































Capecitabine FUP PFS Positive Abse
nt 
- - - - - - - - 
Yamaz
aki K et 
Metas







































































































n.s. n.s. n.s. n.s. 
Aparici



















































FOLFOX  PFS Positive  Abse
nt 
- - - - - - - - 
Yamad





































* declared in the protocol but results not present in the work 
5-FU: 5-Fluorouracil; CAPOX: Capecitabine-Oxaliplatin; EQ5D: Euro Qol five-dimensional questionnaire; EORTC QLQ-C30: European Organization for 
Research and Treatment of Cancer-Quality of Life Questionnaire-Core 30; EORTC QLQ-CR29: European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire-Colorectal Cancer 29; FACT-C: Functional Assessment of Cancer Therapy- Colorectal cancer;  FACT-GOG/Ntx: 
FACT-Gynecologic Oncology Group/Neurotoxicity; FLOX: 5FU- Leucovorin- Oxaliplatin; FOLFIRI: 5FU-Leucovorin-Irinotecan; FOLFOX: 5FU-Leucovorin-
Oxaliplatin; FOLFOXIRI: 5FU-Leucovorin-Irinotecan-Oxaliplatin; FUP: Follow up; mFOLFOX: modified FOLFOX; n.s.: not specified; OS: overall survival; 
PFS: progression-free survival; QoL VAS: QoL-Visual Analogue Scale; QoL: Quality of Life; SIRT: selective internal radiotherapy; TCD: Tumor control 
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* We have considered these studies as separated because two different publications were issued. 
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Table 5. Inclusion of health-related quality of life among study endpoints according to characteristics 
of study and publication. 








QoL not included 
among  
Endpoints 
Whole series 67 1 (1.5%) 25 (37.3%) 41 (61.2%) 
Year of primary 
manuscript 
    
2012  9 - 4 (44.4%) 5 (55.6%) 
2013 11 - 5 (45.5%) 6 (54.5%) 
2014 7 - 1 (14.3%) 6 (85.7%) 
2015 16 - 7 (43.8%) 9 (56.2%) 
2016 9 - 3 (33.3%) 6 (66.7%) 
2017 4 1 (25.0%) 1 (25.0%) 2 (50.0%) 
2018 11 - 4 (36.4%) 7 (63.6%) 
Journal Impact Factor     
Low (<15) 29 1 (3.4%) 8 (27.6%) 20 (69.0%) 
Intermediate (15-
30) 
31 - 14 (45.2%) 17 (54.8%) 
High (>30) 7 - 3 (42.9%) 4 (57.1%) 
Sources of funding     
Profit 26 1 (3.8%) 11 (42.3%) 14 (53.9%) 
Non-profit 41 - 14 (34.1%) 27 (65.9%) 
Setting of disease     
Adjuvant/neoadjuva
nt setting 
20 - 3 (15.0%) 17 (85.0%) 
First-line or 
maintenance setting 
26 - 13 (50.0%) 13 (50.0%) 
Second and further 
lines 
21 1 (4.8%) 9 (42.8%) 11 (52.4%)  
Study design     
Superiority 53 1 (1.9%) 18 (34.0%) 34 (64.1%) 
Non-inferiority 14 - 7 (50%) 7 (50.0%) 
Masking     
Open label 52 - 17 (32.7%) 35 (67.3%) 
Blinded 15 1 (6.7%) 8 (53.3%) 6 (40%) 
Type of experimental therapy*    
Chemotherapy +/- 
other 
52 - 17 (32.7%) 35 (67.3%) 
Targeted therapy 
+/- other 
40 1 (2.5%) 18 (45.0%) 21 (52.5%) 
Primary endpoint     
Overall survival  21 - 10 (47.6%) 11 (52.4%) 
Other 46 1 (2.2%) 15 (32.6%) 30 (65.2%) 
Study result     
Positive  32 1 (3.1%) 11 (34.4%) 20 (62.5%) 
Negative 35 - 14 (40.0%) 21 (60.0%) 




Table 6. Details about health-related quality of life in trials 
 Number of 
publications 
QoL results  
available in primary 
publication 
QoL results 
absent in primary 
publication 
Whole series 67 16 (23.9%) 51 (76.1%) 
Year of primary manuscript    
2012  9 2 (22.2%) 7 (77.8%) 
2013 11 3 (27.3%) 8 (72.7%) 
2014 7 1 (14.3%) 6 (85.7%) 
2015 16 5 (31.2%) 11 (68.8%) 
2016 9 1 (11.1%) 8 (88.9%) 
2017 4 1 (25.0%) 3 (75.0%) 
2018 11 3 (27.3%) 8 (72.7%) 
Journal Impact Factor    
Low (<15) 29 4 (13.8%) 25 (86.2%) 
Intermediate (15-30) 31 10 (32.3%) 21 (67.7%) 
High (>30) 7 2 (28.6%) 5 (71.4%) 
Sources of funding    
Profit 26 7 (26.9%) 19 (73.1%) 
Non-profit 41 9 (21.9%) 32 (78.1%) 
Setting of disease    
Adjuvant/neoadjuvant setting 20 1 (5.0%) 19 (95.0%) 
First-line or maintenance setting 26 8 (30.8%) 18 (69.2%) 
Second and further lines 21 7 (33.3%) 14 (66.7%) 
Study design    
Superiority 53 10 (18.9%) 43 (81.1%) 
Non-inferiority 14 6 (42.9%) 8 (57.1%) 
Masking    
Open label 52 10 (19.2%) 42 (80.8%) 
Blinded 15 6 (40.0%) 9 (60.0%) 
Type of experimental therapy*    
Chemotherapy +/- other 52 8 (15.4%) 44 (84.6%) 
Targeted therapy +/- other 40 13 (32.5%) 27 (67.5%) 
Primary endpoint    
Overall survival  21 6 (28.6%) 15 (71.4%) 
Other 46 10 (21.7%) 36 (78.3%) 
Study result    
Positive  32 12 (37.5%) 20 (62.5%) 
Negative 35 4 (11.4%) 31 (88.6%) 
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